Nasopharyngeal News and Research

RSS

New nasopharyngeal swabs move into human trials for COVID-19

Researchers at the Wyss Institute at Harvard University, in collaboration with healthcare, research, and industrial partners, have designed a new, fully injection-molded nasopharyngeal swab that can be manufactured quickly and inexpensively at high volume to help address the nationwide and international shortage of swabs for COVID-19 testing and research.

28 Apr 2020

SARS-CoV-2 readily infects human intestinal cells in a laboratory model

A new Dutch study available on bioRxiv uses differentiated human small intestinal organoids in vitro to demonstrate that intestinal epithelium supports the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and elicits a strong generic immune response.

27 Apr 2020

Oncologist and mum-to-be chronicles COVID-19 experiences

Writing in the latest issue of JAMA Oncology researcher Coral Olazagasti along with her Dr. Nagashree Seetharamu from Zucker School of Medicine at Hofstra, Northwell Health, Hempstead, New York, spoke about her experience being pregnant during the present COVID-19 pandemic. Olazagasti’s chronicle is titled “Facing a pandemic while pregnant.”

26 Apr 2020

Indiana State Department of Health and IU collaborate to study COVID-19 spread

The Indiana State Department of Health is collaborating with the Indiana University Richard M. Fairbanks School of Public Health at IUPUI to conduct a scientific study to measure the spread of COVID-19 throughout the state.

24 Apr 2020

Researchers use mathematical curves to predict evolution in COVID-19 outbreak

Efforts to contain the spread of the Covid-19 pandemic are now the top priority of governments across the globe. As they make these life-saving decisions, it is particularly crucial for policymakers to accurately predict how the spread of the virus will change over time.

24 Apr 2020

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.

23 Apr 2020

Is hydroxychloroquine effective against COVID-19?

Following the emergence of a novel coronavirus in Wuhan, China, in the last month of 2019, it has spread globally to produce the first pandemic of the 21st century. The virus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has already affected over 2.5 million and killed more than 177,000 people as of April 22, 2020.

22 Apr 2020

Does high COVID-19 viral load mean more risk of infection?

The risk of getting infected with COVID-19 disease is higher among healthcare workers who are in close contact with infected patients

21 Apr 2020

New biosensor rapidly detects SARS-CoV-2 from nasopharyngeal swabs

According to many experts, early diagnosis and management are critical for slowing the spread of SARS-CoV-2, the new coronavirus that causes COVID-19.

20 Apr 2020

Antibody detection for COVID-19 - promise and risks

Recently, several research groups emphasized how the pervasive screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may prove pivotal in determining infection seroprevalence in a given population defining previous exposure, screening health care workers, but also identifying highly reactive individuals that may act as donors for the therapeutic use of their convalescent serum.

20 Apr 2020

Hydroxychloroquine and azithromycin treatment in 80 COVID-19 patients: short-term outcomes

The COVID-19 pandemic is still spreading around the world and affecting nearly 2.4 million people, with over 164,000 dead so far. With neither vaccine nor proven therapeutic drug being available so far, the need of the hour is for effective treatment. Now, a new study reports the potential usefulness of a combination of hydroxychloroquine and azithromycin as a treatment in mild cases of COVID-19 infection and urges the need for further evaluation and widespread use if its findings are confirmed.

19 Apr 2020

FDA approves new Rutgers saliva test for coronavirus

The FDA has granted emergency use authorization to Rutgers' RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency.

13 Apr 2020

Chinese newborns experienced mild form of COVID-19

A new paper published by Dr. Zhi-Jiang Zhang and colleagues from Wuhan University in the European Respiratory Journal in April 2020 reports that COVID-19 apparently left little impact on newborns born to infected mothers at the height of the epidemic.

9 Apr 2020

Experimental drug APN01 prevents COVID-19 infection in the lab

With the world gripped with the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a frantic rush to find an effective drug that can be used to treat the disease.

6 Apr 2020

Virological findings from Germany's first group of COVID-19 patients

In early February, research teams from Charité - Universitätsmedizin Berlin, München Klinik Schwabing and the Bundeswehr Institute of Microbiology published initial findings describing the efficient transmission of SARS-CoV-2.

3 Apr 2020

Who should be taking antimalarial drugs as treatment against COVID-19?

Researchers provide a guideline regarding who should be actually taking antimalarial drugs as prophylaxis to prevent getting COVID-19. They say health professionals who are being exposed to COVID-19 positive patients and those who test positive but are asymptomatic should be taking drugs such as Chloroquine and Hydroxychloroquine. They explain that these populations remain most in need, and because of limited supply, these individuals need to be prioritized.

2 Apr 2020

New Vivalytic Viral Respiratory Tract Infection Array can identify SARS-CoV-2 virus

A game-changing point of care coronavirus test from global diagnostics company Randox Laboratories and leading technology manufacturer Bosch Healthcare Solutions will launch in April 2020.

From Randox Laboratories Ltd. 1 Apr 2020

Spit and feces test positive for SARS CoV-2 even after recovery

A new study reveals that samples of sputum and feces continue to test positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus even after a person has recovered from COVID-19 and nasopharyngeal secretions test negative for the virus.

31 Mar 2020

Robots and drones can help curb the coronavirus pandemic

Can robots provide an effective method to combat the COVID-19 pandemic? A team of robotic leaders, including Henrik Christensen, the director of UC San Diego’s Contextual Robotics Institute, believes that healthcare systems can use robots for a variety of purposes.

26 Mar 2020

Pets, the novel coronavirus and COVID-19 disease

Can dogs and other pets play a role in the transmission of the novel coronavirus? The question has surfaced after a Pomeranian in Hong Kong tested positive for the SARS-CoV-2 or the novel coronavirus last week.

19 Mar 2020